title: MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression.
abstract: BACKGROUND
  Demyelination and failure of remyelination are core mechanisms in the pathogenesis of multiple sclerosis (MS); the factor(s) modulating these processes are still mostly unknown. MicroRNA 572 (miR-572) is deregulated in MS and is suggested to targets neural cell adhesion molecule (NCAM), a glycoprotein involved in CNS reparative mechanisms. The aim of this study is to analyze miR-572 in patients with different clinical phenotypes of MS.
  
  
  METHODS
  qPCR quantification of miR-572 isolated from serum was performed in 16 primary progressive (PP), 15 secondary progressive (SP), 31 relapsing remitting (RR) MS patients and 15 sex-and age-matched healthy controls.
  
  
  RESULTS
  miR-572 expression was reduced overall in MS patients (p < 0.05) compared to HC; this miRNA was significantly upregulated in SPMS and in RRMS during disease relapse, whereas it was downregulated in PPMS and in quiescent phases of RRMS. miR-572 expression correlated with EDSS scores (RSp = 0.491; p < 0.05) independently of the clinical phenotype. The results suggest that this miRNA might be a tool that helps distinguishing between PPMS and SPMS and between relapsing and remitting phases in RRMS.
  
  
  CONCLUSIONS
  Evaluation of miR-572 may serve as a non-invasive biomarker for remyelination.
authors.affiliation: Don C. Gnocchi Foundation - ONLUS, P.zza Morandi, 3, 20100, Milano, Italy. rmancuso@dongnocchi.it.
authors.forename: Roberta
authors.initials: R
authors.lastname: Mancuso
authors.affiliation: Don C. Gnocchi Foundation - ONLUS, P.zza Morandi, 3, 20100, Milano, Italy. ahernis@dongnocchi.it.
authors.forename: Ambra
authors.initials: A
authors.lastname: Hernis
authors.affiliation: Don C. Gnocchi Foundation - ONLUS, P.zza Morandi, 3, 20100, Milano, Italy. sagostini@dongnocchi.it.
authors.forename: Simone
authors.initials: S
authors.lastname: Agostini
authors.affiliation: Don C. Gnocchi Foundation - ONLUS, P.zza Morandi, 3, 20100, Milano, Italy. mrovaris@dongnocchi.it.
authors.forename: Marco
authors.initials: M
authors.lastname: Rovaris
authors.affiliation: Don C. Gnocchi Foundation - ONLUS, P.zza Morandi, 3, 20100, Milano, Italy. dcaputo@dongnocchi.it.
authors.forename: Domenico
authors.initials: D
authors.lastname: Caputo
authors.affiliation: Don C. Gnocchi Foundation - ONLUS, P.zza Morandi, 3, 20100, Milano, Italy. mario.clerici@unimi.it.|Department of Physiopathology and Transplantation, University of Milano, Milano, Italy. mario.clerici@unimi.it.
authors.forename: Mario
authors.initials: M
authors.lastname: Clerici
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000378:metabolism; D019002:CD56 Antigen / Q000378:metabolism; D016022:Case-Control Studies; D018450:Disease Progression; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000235:genetics / Q000378:metabolism*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000235:genetics / Q000378:metabolism*; D009186:Myelin Sheath / Q000378:metabolism; D010641:Phenotype; D012008:Recurrence
chemical_list: D015415:Biomarkers; D019002:CD56 Antigen; C000603872:MIRN-572 microRNA, human; D035683:MicroRNAs; C522918:NCAM1 protein, human